Gene therapy company Real And Best accelerates to promote pipelines covering genetic disease, metabolism, and aging
Real And Best (Chinese: 至善唯新) completed a over CNY 200 million Series A+ financing round, which was led by SDIC Venture Capital (Chinese: 国投创业) and followed by PanLin Capital (Chinese: 磐霖资本) and Anxin Guosheng Weixin Fund (Chinese: 安信国生微芯基金). The backer Loyal Valley Capital (Chinese: 正心谷资本) continues to invest. BMD Capital (Chinese: BMD资本) acted as the exclusive financial adviser.
Proceeds raised in this round will be mainly used in the clinical promotion of existing product pipelines, the expansion of preclinical pipelines, and the expansion of talent teams.
Founded in June 2018, Real And Best is a biotech company focusing on the R&D of Recombinant RAVN virus (rAAV). It has a number of world-leading patents and technologies in efficient gene expression cassette design and vector production optimization. The existing pipelines cover multiple clinical indications such as blood, central nervous system, and metabolic system. The company owns the world-leading new adenovirus-poxviruses rAAV production system can significantly reduce production cost and further increase the availability of gene therapy. Its self-developed gene therapy product ZS801 received clinical trials approval from NMPA, which was the first approved gene therapy targeting Haemophilia B in China. Now research to testify the therapy's safety and efficacy has been conducted in Chinese Academy of Medical Sciences.
Real And Best's competitors include OrienGene (Chinese: 奥源和力), Belief BioMed (Chinese: 信念医药) and Innostellar Biotherapeutics (Chinese: 朗信生物).